Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 14OTHER 8NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 90Prostatic Neoplasms 55Lymphoma 34Leukemia 32Carcinoma, Non-Small-Cell Lung 31Multiple Myeloma 30Head and Neck Neoplasms 30Colorectal Neoplasms 29Squamous Cell Carcinoma of Head and Neck 28Lung Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Colonic Neoplasms 24Leukemia, Myeloid, Acute 22Rectal Neoplasms 21Neoplasm Metastasis 20Sarcoma 19Ovarian Neoplasms 19Central Nervous System Neoplasms 18Uterine Cervical Neoplasms 17Hodgkin Disease 17Burkitt Lymphoma 15Brain Neoplasms 15Carcinoma, Ovarian Epithelial 14Pain 12Lymphoma, Follicular 12Urinary Bladder Neoplasms 11Lymphoma, Large B-Cell, Diffuse 11Fallopian Tube Neoplasms 11Endometrial Neoplasms 11Astrocytoma 11

Interventions

S 1 (combination) 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NETWORK × Biliary Tract Neoplasms × Clear all
NCT02182778 2019-02-21

GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

Kansai Hepatobiliary Oncology Group

Phase 3 Completed
246 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡